Today’s news that Skyepharma is partnering its triple combination product, SKP-2076, with Mundipharma is very encouraging and expands on their already established relationship for flutiform®. Skyepharma and Mundipharma’s partnership for flutiform® has proven to be very successful with the product continuing to generate substantial growth. SKP-2076 was recently disclosed as a triple therapy combination product for asthma incorporating known chemical entities, reducing the product’s development ri ....
